Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio IM027-1026  |   NCT06568458

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Ninetedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Resumen

  • Phase 1
  • Ícono de género masculino y femenino
  • 18-65
  • 1
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
:
  • Participants must be healthy males and females (INOCBP)
    1. Participant must have Body mass index (BMI) of 18.0 kg/m2 through 32.0 kg/m2, inclusive.
      1. Participant must have Body weight ≥ 50 kg

        Criterios de exclusión

        Criterios de exclusión Icon
        :
        • Participant must not have current or recent GI disease
          1. Participant with evidence of organ dysfunction or any clinically significant deviation, as determined by investigator, from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population.
            1. Participant with prior exposure to BMS-986278 and exposure of any investigational drug or placebo within 4 weeks of study intervention administration.
              Información Adicional *
              • Other protocol-defined Inclusion/Exclusion criteria apply.

                Opciones de tratamiento

                Brazos del estudio

                INTERVENCIÓN ASIGNADA

                Brazos del estudio

                Experimental: Part I: Period A

                INTERVENCIÓN ASIGNADA
                • Drug: Nintedanib

                Brazos del estudio

                Experimental: Part I: Period B

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278

                Brazos del estudio

                Experimental: Part I: Period C

                INTERVENCIÓN ASIGNADA
                • Drug: Nintedanib, BMS 986278

                Brazos del estudio

                Experimental: Part II: Period 1

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278

                Brazos del estudio

                Experimental: Part II: Period 2

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278

                Brazos del estudio

                Experimental: Part II: Period 3

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278

                Brazos del estudio

                Experimental: Part III: Period 1

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278

                Brazos del estudio

                Experimental: Part III: Period 2

                INTERVENCIÓN ASIGNADA
                • Drug: BMS 986278
                Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                Verifique su elegibilidad
                Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                Compatibilizar con un estudio
                Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                Seleccione una ubicación del centro del estudio
                Seleccione una ubicación del centro del estudio que sea conveniente para usted
                Registrarse
                Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias